This invention relates to a method of using MOF adsorbents to remove elemental impurities from feed streams comprising active pharmaceutical ingredients (API). The process involves contacting the feed stream comprising API and elemental impurities with the MOF at purification conditions to obtain a purified stream with provides an API which has a concentration of the elemental impurity below its permitted daily exposure. The process can be carried in a batch mode where the MOF and feed stream are admixed in a vessel for a given amount of time or continuously by flowing the feed stream through a column or adsorbent bed containing the MOF adsorbent.

A method for the treatment of silicon-containing wastewater from the preparation of a molecular sieve or a catalyst includes the step of contacting the silicon-containing wastewater with at least one acid or at least one alkali, so that at least a part of the silicon elements in the silicon-containing wastewater form a colloid. A mixture containing a colloid is thus obtained. A silicon-containing solid phase and a first liquid phase are produced by a solid-liquid separation. A solid phase and a second liquid phase are produced by a solid-liquid separation after at least a part of the metal elements in the first liquid phase form a precipitate. At least a part of the second liquid phase is subjected to electrodialysis to produce an acid liquor and/or an alkali liquor. The silicon-containing solid phase can be used as the raw material for a molecular sieve synthesis.

A method for the treatment of silicon-containing wastewater from the preparation of a molecular sieve or a catalyst includes the step of contacting the silicon-containing wastewater with at least one acid or at least one alkali, so that at least a part of the silicon elements in the silicon-containing wastewater form a colloid. A mixture containing a colloid is thus obtained. A silicon-containing solid phase and a first liquid phase are produced by a solid-liquid separation. A solid phase and a second liquid phase are produced by a solid-liquid separation after at least a part of the metal elements in the first liquid phase form a precipitate. At least a part of the second liquid phase is subjected to electrodialysis to produce an acid liquor and/or an alkali liquor. The silicon-containing solid phase can be used as the raw material for a molecular sieve synthesis.

Disclosed herein are modified zeolites and methods for making modified zeolites. In one or more embodiments disclosed herein, a modified zeolite may include a microporous framework including a plurality of micropores having diameters of less than or equal to 2 nm. The microporous framework may include at least silicon atoms and oxygen atoms. The modified zeolite may further include organometallic moieties each bonded to a nitrogen atom of a secondary amine functional group comprising a nitrogen atom and a hydrogen atom. The organometallic moieties may comprise a hafnium atom that is bonded to the nitrogen atom of the secondary amine functional group. The nitrogen atom of the secondary amine function group may bridge the hafnium atom of the organometallic moiety and a silicon atom of the microporous framework.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to a crystallised solid, called IZM-5, comprising a chemical composition expressed on an anhydrous base, in terms of mole, and defined by the following general formula: Sn.sub.aZn.sub.bS.sub.8: cR, wherein R represents at least one nitrogenous organic species; S sulphur, “a” is the molar amount of tin, denoted Sn, between 0.1 and 5; “b” is the molar amount of zinc, denoted Zn, between 0.2 and 8; “c” is the molar amount of the nitrogenous organic species R between 0 and 4.

Metal-organic framework materials (MOFs) are highly porous entities comprising a multidentate organic ligand coordinated to multiple metal centers, typically as a coordination polymer. MOFs may comprise a plurality of metal centers, and a multidentate organic ligand coordinated via at least two binding sites to the plurality of metal centers to define an at least partially crystalline network structure having a plurality of internal pores, and in which the multidentate organic ligand comprises first and second binding sites bridged together with a third binding site comprising a diimine moiety. The multidentate organic ligand may comprise a reaction product of a vicinal dicarbonyl compound and an amine-substituted salicylic acid to define the first, second and third binding sites. Particular MOFs may comprise 5,59′-(((1E,2E)-ethane-1,2-diylidene)bis-(azaneylylidene))bis(2-hydroxybenzoic acid) as a multidentate organic ligand.

Metal-organic framework materials (MOFs) are highly porous entities comprising a multidentate organic ligand coordinated to multiple metal centers, typically as a coordination polymer. MOFs may comprise a plurality of metal centers, and a multidentate organic ligand coordinated via at least two binding sites to the plurality of metal centers to define an at least partially crystalline network structure having a plurality of internal pores, and in which the multidentate organic ligand comprises first and second binding sites bridged together with a third binding site comprising a diimine moiety. The multidentate organic ligand may comprise a reaction product of a vicinal dicarbonyl compound and an amine-substituted salicylic acid to define the first, second and third binding sites. Particular MOFs may comprise 5,59′-(((1E,2E)-ethane-1,2-diylidene)bis-(azaneylylidene))bis(2-hydroxybenzoic acid) as a multidentate organic ligand.

An inorganic porous carrier including a linker of formula (1), wherein a mode diameter in a pore distribution is 0.04 μm to 1 μm, and a predetermined cumulative pore volume ratio is 30% or less [a bond * represents a linkage to the oxygen atom of a silanol group in an inorganic porous substance; n is an integer; R represents independently of each other an alkyl group containing 3 to 10 carbon atoms which may optionally have a substituent such as an alkoxy group; and L represents a single bond; an alkylene group of 1 to 20 carbon atoms; or an alkylene group containing 2 to 20 carbon atoms which contains —CH.sub.2-Q-CH.sub.2— group wherein any group Q selected from a group consisting of —O— etc. is inserted into at least one of —CH.sub.2—CH.sub.2— group constituting the alkylene group]; and a method for preparing a nucleic acid using the same.

##STR00001##